Tyrvaya's New Home: A Test for Harrow's Growth Ambitions The recent acquisition of Tyrvaya nasal spray by Harrow, Inc.
has sent ripples through the pharmaceutical industry, raising questions about its potential to become a growth engine for its new owner. On August 6, Harrow announced a definitive agreement with Viatris, Inc.
to acquire global rights to Tyrvaya for up to $100 million. At first glance, the deal appears to be a savvy move by Harrow to bolster its portfolio and capitalize on Viatris's established sales team.